In this episode of Beyond Tomorrow, the hosts explore the cutting-edge science of rejuvenation and organ replacement. Guests Will Harborne and Sebastian Brunemeier, from LongGame Ventures discuss how advances in biotechnology and lifestyle strategies could help humans extend their healthspan—and perhaps even “upgrade” their own organs.

Key Points:

This episode explores how organ regeneration, biotechnology, and lifestyle optimization could redefine the way we age. Will Harborne and Sebastian Brunemeier share their visions of a future where extending healthspan becomes achievable through scientific innovation and data-driven living. As longevity biotechnology continues to advance, the discussion also highlights the need to balance the promise of “upgrading ourselves” with critical considerations around equity, ethics, and the broader purpose of human enhancement.

• Rejuvenation as the Next Frontier – The discussion centers on how organ regeneration and replacement could transform aging from an inevitable decline into a manageable biological process.
• From Repair to Replacement – Brunemeier explains how emerging biotechnologies aim to replace failing organs with lab-grown or engineered alternatives, offering new hope for extending vitality.
• Will Harborne’s Perspective – Harborne highlights the role of supplements, nutrition, and data-driven lifestyle interventions in slowing biological aging while society awaits full regenerative solutions.
• Merging Tech and Biology – Both guests emphasize that combining AI, cellular reprogramming, and tissue engineering could accelerate breakthroughs in personalized health restoration.
• Ethical and Social Questions – The conversation touches on who will benefit from these technologies first and how access to organ “upgrades” might deepen health inequalities.
• From Longevity to Quality of Life – Rather than just living longer, both speakers argue for improving the years we already have—reducing disease risk and maintaining physical and cognitive performance.
• Investment and Innovation Landscape – Brunemeier discusses how venture capital is increasingly backing companies developing rejuvenation therapies, signaling growing confidence in longevity biotech.
• Human Enhancement vs. Healing – The episode explores where the line between medical necessity and elective enhancement might blur as regenerative technologies mature.